Key facts
- ImmuneSpec’s last known valuation is $5.3M (Mar 2025).
- It has raised $2.4M; the latest was Seed Round ($2.4M) in Mar 2025.
- Notable investors include HERAN Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for ImmuneSpec
- ·The full record, as it builds
Funding rounds
No funding rounds for ImmuneSpec are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ImmuneSpec
Developer of an immune peptidomics platform designed for a faster, more accurate identification of immunogenic peptides. The company specializes in a renewed, mass spectrometry (MS)-based approach for the identification of tumor antigens with immunopeptidomics, enabling clients like life science companies and biotech companies to have assistance in the development of broad-spectrum vaccines, personalized medicine, and immunotherapeutics.
- Sector
- Healthcare
- HQ
- Antwerp, Belgium
- Founded
- 2023
- Employees
- 9
- Website
- immunespec.com/
- Ownership
- Privately Held (backing)
ImmuneSpec doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ImmuneSpec shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ImmuneSpec in its N-PORT filings yet. We sweep new filings monthly.